March 25th, 2013
Posted by Patti Doherty, R.N.
Review any drug’s development history: Clearly, the execution of clinical trials makes up the lion’s share of the timeline. To further complicate matters and extend development timelines, as more drugs are being developed on a global basis, it’s more difficult to keep a clinical trial on target with multiple sites around the world, site qualification visits, and record keeping. In fact, 80% of today’s clinical trials fail to meet one or more milestones. Fortunately, digital technologies – increasingly being adopted by contract research organizations (CROs) and larger biopharmaceutical companies – may offer a way around the limitations of today’s paper-based practices.
Recently, Johnson & Johnson, Merck & Co. and Eli Lilly & Co. announced their plans to create a database of global clinical trial sites, which would streamline any participating trial’s significant paperwork requirements. The database would contain site and experimental infrastructure details, and good clinical practice GCP records. The partners will be presenting their progress at the Partnerships in Clinical Trials meeting in April.
Read the rest of this entry »